File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma

TitleA phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma
Authors
Yau, CCChan, PPang, RChan, WCheng, PNPoon, R
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2010
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010), Chicago, IL., 4-8 June 2010. In Journal of Clinical Oncology, 2010, v. 28 n. 15 suppl., abstract e13503 How to Cite?
AbstractBACKGROUND: Patients (pts) with advanced hepatocellular carcinoma (HCC) have a poor prognosis. Pre-clinical data suggest that HCC cells are auxotrophic for arginine through the lack of expression of argininosuccinate synthetase. Recombinant human arginase I (rhArgI) is a novel compound which can achieve near total depletion of plasma arginine. A phase Ia/Ib, open-label, dose-escalation study was conducted to determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of rhArgI in …
DescriptionThis journal suppl. contain abstracts of ASCO 2010
Open Access Journal
Persistent Identifierhttp://hdl.handle.net/10722/186981
ISSN
0732-183X
2023 Impact Factor: 42.1
2023 SCImago Journal Rankings: 10.639

 

DC FieldValueLanguage
dc.contributor.authorYau, CCen_US
dc.contributor.authorChan, Pen_US
dc.contributor.authorPang, Ren_US
dc.contributor.authorChan, Wen_US
dc.contributor.authorCheng, PNen_US
dc.contributor.authorPoon, Ren_US
dc.date.accessioned2013-08-20T12:26:34Z-
dc.date.available2013-08-20T12:26:34Z-
dc.date.issued2010en_US
dc.identifier.citationThe 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010), Chicago, IL., 4-8 June 2010. In Journal of Clinical Oncology, 2010, v. 28 n. 15 suppl., abstract e13503en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/186981-
dc.descriptionThis journal suppl. contain abstracts of ASCO 2010-
dc.descriptionOpen Access Journal-
dc.description.abstractBACKGROUND: Patients (pts) with advanced hepatocellular carcinoma (HCC) have a poor prognosis. Pre-clinical data suggest that HCC cells are auxotrophic for arginine through the lack of expression of argininosuccinate synthetase. Recombinant human arginase I (rhArgI) is a novel compound which can achieve near total depletion of plasma arginine. A phase Ia/Ib, open-label, dose-escalation study was conducted to determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of rhArgI in …-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleA phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailYau, CC: tyaucc@hku.hken_US
dc.identifier.emailPang, R: robertap@hku.hken_US
dc.identifier.emailPoon, R: poontp@hku.hken_US
dc.identifier.authorityYau, CC=rp01466en_US
dc.identifier.authorityPang, R=rp00274en_US
dc.identifier.authorityPoon, R=rp00446en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros217130en_US
dc.identifier.volume28-
dc.identifier.issue15 suppl.-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 131007-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats